Kidney transplant study comparing a new medicine to a standard one
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study compares a new medicine called tegoprubart with a standard medicine called tacrolimus for people who are getting a kidney transplant. The goal is to see if the new medicine is safe and works as well as or better than the standard one to keep the new kidney healthy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You are scheduled to receive a kidney transplant from a living or deceased donor
- You are willing to give written consent to participate
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is a long-term follow-up study for people who have already completed a study of the drug tegoprubart after a kidney transplant. It checks how safe and effective the drug is over a longer period.
This trial compares a new drug called frexalimab to the standard drug tacrolimus in people who are getting their first kidney transplant. The goal is to see if frexalimab works better and has a safer side effect profile.
This study looks at different treatments for a type of kidney transplant rejection called antibody-mediated rejection, where the body's immune system attacks the new kidney. It aims to understand how these treatments work and how they might help people keep their transplanted kidney healthy.
This study tests a new medicine called TNX-1500 that may help prevent the body from rejecting a new kidney. It is for people who are already waiting for a kidney transplant and aims to make the transplant more successful.
This trial is testing a way to help your body accept a kidney transplant without needing lifelong anti-rejection drugs. It is for people getting a kidney from a living donor who is a relative and has a compatible blood type.
This study looks at how well a once-daily anti-rejection medicine (Envarsus) works in people who have just had a kidney transplant. It helps doctors understand the best way to use this medicine and manage side effects.
Hear when a new Kidney Transplant Rejection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.